|
|
 |
|
|
|
|
published in proceedings of Cost B1 European Conference on specificity and variability in drug metabolism. Besançon, 1012 May 1995. |
|
|
|
|
|
|
|
|
36. G. Alván. Clinical consequences of polymorphic drug metabolism. Fundam. Clin. Pharmacol. 5: 209228, 1991. |
|
|
|
|
|
|
|
|
37. J. A. G. Agúndez, M. C. Lesesma, J. Benítez, J. M. Ladero, A. Rodríguez-Lescure, E. Díaz-Rubio, M. Díaz-Rubio. CYP 2D6 genes and risk of liver cancer. Lancet 345: 830831, 1995. |
|
|
|
|
|
|
|
|
38. R. A. Cartwright, R. W. Glashan, H. J. Rogers, R. A. Ahmad, D. Barham-Hall, E. Higgins, and M. A. Kahn. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet ii: 842845, 1982. |
|
|
|
|
|
|
|
|
39. C. A. D. Smith, A. C. Gough, N. P. Leigh, B. A. Summers, A. E. Harding, D. M. Maranganore, S. G. Sturman, A. H. V. Schapira, A. C. Williams, N. K. Spurr, and C. R. Wolf. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's Disease. Lancet 339: 13751377, 1992. |
|
|
|
|
|
|
|
|
40. A. Rane, G. R. Wilkinson, and D. G. Shand. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200: 420424, 1977. |
|
|
|
|
|
|
|
|
41. A. J. Houston. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47: 14691479, 1994. |
|
|
|
|
|
|
|
|
42. B. A. Hoener. Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Dispos. 15: 295304, 1994. |
|
|
|
|
|
|
|
|
43. G. Ubeaud, C. Schmitt, D. Jaeck, T. Lave, and P. H. Coassolo. Bosentan: a new endothelin receptor antagonist: prediction of a systemic plasma clearance in man from combined in vivo and in vitro data. Xenobiotica 25: 13811390, 1995. |
|
|
|
|
|
|
|
|
44. P. G. Welling and F. A. De La Iglesia. Drug Toxicokinetics: Drug and Chemical Toxicology Series No. 9. Marcel Dekker, New York, 1993. |
|
|
|
|
|
|
|
|
45. D. B. Campbell and R. M. J. Ings. New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicol. 7: 469479, 1988. |
|
|
|
|
|
|
|
|
46. E. F. Adolphe. Quantitative relations in the physiological constituents of mammals. Science 109: 579585, 1949. |
|
|
|
|
|
|
|
|
47. H. Boxenbaum. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokin. Biopharma. 10: 201227, 1982. |
|
|
|
|
|
|
|
|
48. D. B. Campbell. Sizing up the problem of exposure extrapolation: New directions in allometric scaling in toxicology of industrial compounds. H. Thomas, R. Hess, and F. Waechter, Eds. Taylor and Francis, London, 1995, p. 4558. |
|
|
|
|
|
|
|
|
49. M. Bonati, R. Latini, G. Tognoni, J. F. Young, and S. Garattini. Interspecies comparison of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Metabolism Rev. 15: 13551383, 198485. |
|
|
|
|
|
|
|
|
50. G. A. Sacher. Relation of lifespan to brain weight and body weight in mammals. In The Life Span of Animals. G. E. W. Wolstenholme and M. O'Connor, Eds. Little Brown, Boston, 1959, p. 115141. |
|
|
|
|
|
|
|
|
51. H. Boxenbaum and R. De Souza. Physiological models, allometry, neoteny, space time and pharmacokinetics. In Pharmacokinetics: Mathematical and Statistical Approaches. A. Peale and A. Resagno, Eds. Plenum, New York, 1988. |
|
|
|
|
|